Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients

Thomas G. Knight, MD, Melissa Aguiar, MSN, RN, Myra Robinson, MSPH, Allison Martin, PharmD, Tommy Chen, BS, Rupali Bose, MS, MBA, Jing Ai, MDPhD, Brittany K. Ragon, MD, Aleksander L. Chojecki, MD, Nilay A. Shah, MD, Srinivasa R. Sanikommu, MD, James Symanowski, PhD, Edward A Copelan, Michael R. Grunwald, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137222

Published: 2020

Journal Articles

Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients

Issam S. Hamadeh, PharmD, Michael R. Grunwald, MD, Allison Martin, PharmD, Jai N. Patel, PharmD, Alexandra Shillingburg, PharmD, Ekaterina Kachur, PharmD, Allene COOK, PharmD, Allison Karabinos, PharmD, Jing Ai, MDPhD, Thomas G. Knight, MD, Brittany K. Ragon, MD, Aleksander L. Chojecki, MD, Nilay A. Shah, MD, Srinivasa R. Sanikommu, MD, Belinda R Avalos, MD, Edward A Copelan, Zainab Shahid, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-141124

Published: 2020

Journal Articles

Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients

Thomas G. Knight, MD, Melissa Aguiar, MSN, RN, Myra Robinson, MSPH, Allison Martin, PharmD, Heather Cranford, CPhT, Tommy Chen, BS, Rupali Bose, MS, MBA, Jing Ai, MDPhD, Brittany K. Ragon, MD, Aleksander L. Chojecki, MD, Nilay A. Shah, MD, Srinivasa R. Sanikommu, MD, James Symanowski, PhD, Edward A Copelan, Michael R. Grunwald, MD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-136578

Published: 2020

Journal Articles

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Issam S. Hamadeh, PharmD, Justin Arnall, Pharm.D., Ekaterina Kachur, PharmD, Allison Martin, PharmD, Megan Helena Jagosky, MD, Reed Friend, MD, Shebli Atrash, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 2255.

https://doi.org/10.1182/blood-2018-99-118737

Published: 2018

Journal Articles

JAK1 and JAK2 Modulate Tumor Cell Susceptibility To Natural Killer (NK) Cells Through Regulation Of PDL1 Expression

Roberto Bellucci, PhD, Allison Martin, BS, Davide Bommarito, Kathy S. Wang, PhD, Gordon J Freeman, PhD, Jerome Ritz, MD

Blood (2013) 122 (21): 3472.

https://doi.org/10.1182/blood.V122.21.3472.3472

Published: 2013

Journal Articles

Enhancement of Tumor Cell Susceptibility to NK Cell Activity Through Inhibition of the PI3K Signaling Pathway.

Davide Bommarito, Allison Martin, BS, Maria-Dorothea Nastke, Jerome Ritz, MD, Roberto Bellucci, PhD

Blood (2012) 120 (21): 2152.

https://doi.org/10.1182/blood.V120.21.2152.2152

Published: 2012

Journal Articles

Targeting the Interferon-γ (IFN-γ) Pathway to Enhance Susceptibility of Multiple Myeloma Tumor Cells to NK Cell Lysis

Roberto Bellucci, PhD, Allison Martin, BS, Davide Bommarito, Jerome Ritz, MD

Blood (2012) 120 (21): 4013.

https://doi.org/10.1182/blood.V120.21.4013.4013

Published: 2012

Journal Articles

JAK1 and JAK2 Modulate Myeloma Cell Susceptibility to NK Cells Through the Interferon Gamma (IFN-γ) Pathway,

Roberto Bellucci, PhD, Allison Martin, BS, Marc Buren, Hong-Nam Nguyen, BS, Davide Bommarito, Jerome Ritz, MD

Blood (2011) 118 (21): 3960.

https://doi.org/10.1182/blood.V118.21.3960.3960

Published: 2011

Journal Articles

NOVEL Pathways Modulate TUMOR CELL Susceptibility to NK CELLS.

Roberto Bellucci, Ph.D, Hong-Nam Nguyen, Allison Martin, Anna C. Schinzel, PhD, Stefan Heinrichs, PhD, William C. Hahn, MD, PhD, Jerome Ritz, MD

Blood (2009) 114 (22): 277.

https://doi.org/10.1182/blood.V114.22.277.277

Published: 2009

Journal Articles

Genetic Screening for Myeloma Cell Susceptibility to NK Cell Mediated Lysis Using Large Lentiviral shRNA Libraries

Roberto Bellucci, Ph.D, Hong-Nam Nguyen, Allison Martin, Anna Schinzel, Ph.D, John Daley, Steen Hansen, M.D., Ph.D, William C. Hahn, M.D., Ph.D, Jerome Ritz, M.D.

Blood (2008) 112 (11): 2900.

https://doi.org/10.1182/blood.V112.11.2900.2900

Published: 2008

NARROW

Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients

Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients

Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

JAK1 and JAK2 Modulate Tumor Cell Susceptibility To Natural Killer (NK) Cells Through Regulation Of PDL1 Expression

Enhancement of Tumor Cell Susceptibility to NK Cell Activity Through Inhibition of the PI3K Signaling Pathway.

Targeting the Interferon-γ (IFN-γ) Pathway to Enhance Susceptibility of Multiple Myeloma Tumor Cells to NK Cell Lysis

JAK1 and JAK2 Modulate Myeloma Cell Susceptibility to NK Cells Through the Interferon Gamma (IFN-γ) Pathway,

NOVEL Pathways Modulate TUMOR CELL Susceptibility to NK CELLS.

Genetic Screening for Myeloma Cell Susceptibility to NK Cell Mediated Lysis Using Large Lentiviral shRNA Libraries

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only